Findings

What do systematic reviews say?

4,760 questions · 8,065 findings · 1,036 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,686 · 20.9%GRADE not reported 675 · 8.4%Very low 1,953 · 24.2%Low 2,048 · 25.4%Moderate 1,296 · 16.1%High 407 · 5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Outpatient vs inpatients ‐ children

Adverse drug reactions · Children with cancer who develop a low‐risk febrile neutropaenic event

Outpatients showed no clear difference in adverse drug reactions compared with inpatients ‐ children (low certainty).

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
RR 1.9 [0.61, 5.98]
2 studies · 156 participants
Low

Outpatient vs inpatients ‐ children

Duration of neutropaenia (days) · Children with cancer who develop a low‐risk febrile neutropaenic event

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 268 participants
Moderate

Outpatient vs inpatients ‐ children

Length of hospitalisation (days) · Children with cancer who develop a low‐risk febrile neutropaenic event

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 119 participants
Low

Outpatient vs inpatients ‐ children

Duration of antimicrobial treatment (days) · Children with cancer who develop a low‐risk febrile neutropaenic event

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 305 participants
Low

Outpatient vs inpatients ‐ adults

All‐cause mortality · Adult patients with cancer who develop a low‐risk febrile neutropaenic event

Outpatients showed no clear difference in mortality compared with inpatients ‐ adults (moderate certainty).

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
RR 1.04 [0.29, 3.71]
6 studies · 628 participants
Moderate

Outpatient vs inpatients ‐ adults

Fever clearance time · Adult patients with cancer who develop a low‐risk febrile neutropaenic event

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 169 participants
Low

Outpatient vs inpatients ‐ adults

Adverse drug reactions · Adult patients with cancer who develop a low‐risk febrile neutropaenic event

Outpatients showed no clear difference in adverse drugs reactions compared with inpatients ‐ adults (low certainty).

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
RR 8.39 [0.38, 187.15]
3 studies · 375 participants
Low

Outpatient vs inpatients ‐ adults

Duration of neutropaenia (days) · Adult patients with cancer who develop a low‐risk febrile neutropaenic event

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 169 participants
Low

Outpatient vs inpatients ‐ adults

Length of hospitalisation (days) · Adult patients with cancer who develop a low‐risk febrile neutropaenic event

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 251 participants
Low

Outpatient vs inpatients ‐ children

Treatment failure · Children with cancer who develop a low‐risk febrile neutropaenic event

Outpatients showed no clear difference in treatment failure compared with inpatients ‐ children (moderate certainty).

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
RR 1.04 [0.55, 1.99]
4 studies · 366 participants
Moderate

Outpatient vs inpatients ‐ children

All‐cause mortality · Children with cancer who develop a low‐risk febrile neutropaenic event

Outpatients showed no clear difference in mortality compared with inpatients ‐ children (moderate certainty).

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
RR 0.63 [0.15, 2.7]
3 studies · 329 participants
Moderate

Outpatient vs inpatients ‐ children

Fever clearance time · Children with cancer who develop a low‐risk febrile neutropaenic event

1 finding from 1 review

Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 305 participants
Low

BTURP vs MTURP

Urological symptom scores · men with lower urinary tract symptoms secondary to benign prostatic obstruction

1 finding from 1 review

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign… 2019 · Cochrane Headline outcomes only
no estimate extracted
16 studies · 2531 participants
Moderate

BTURP vs MTURP

Bother (HRQoLc at 12 months) · men with lower urinary tract symptoms secondary to benign prostatic obstruction

1 finding from 1 review

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign… 2019 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 2004 participants
Moderate

BTURP vs MTURP

TUR syndrome · men with lower urinary tract symptoms secondary to benign prostatic obstruction

BTURP probably leads to lower TUR syndrome compared with MTURP (moderate certainty).

1 finding from 1 review

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign… 2019 · Cochrane Headline outcomes only
RR 0.17 [0.09, 0.3]
44 studies · 6745 participants
Moderate

BTURP vs MTURP

Urinary incontinence late postnatal period (> 6‐12 months) · men with lower urinary tract symptoms secondary to benign prostatic obstruction

BTURP showed no clear difference in urinary incontinence at 12 months compared with MTURP (low certainty).

1 finding from 1 review

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign… 2019 · Cochrane Headline outcomes only
RR 0.2 [0.01, 4.06]
4 studies · 751 participants
Low

BTURP vs MTURP

Blood transfusion · men with lower urinary tract symptoms secondary to benign prostatic obstruction

BTURP probably leads to lower blood transfusion compared with MTURP (moderate certainty).

1 finding from 1 review

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign… 2019 · Cochrane Headline outcomes only
RR 0.42 [0.3, 0.59]
38 studies · 5727 participants
Moderate

BTURP vs MTURP

Re‐TURP · men with lower urinary tract symptoms secondary to benign prostatic obstruction

BTURP showed no clear difference in re‐TURP compared with MTURP (low certainty).

1 finding from 1 review

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign… 2019 · Cochrane Headline outcomes only
RR 1.02 [0.44, 2.4]
6 studies · 652 participants
Low

BTURP vs MTURP

Erectile function · men with lower urinary tract symptoms secondary to benign prostatic obstruction

1 finding from 1 review

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign… 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 321 participants
Moderate

Anti‐TNF dose reduction vs anti‐TNF continuation

Disease activity · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 501 participants
High